Epilepsy
📧 Sign up to get email alerts when something new happens for Epilepsy.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-11-09FDA Approved: LAMOTRIGINE — Supplemental Application (NorthStar Rx LLC)
FDA approved a supplemental application for lamotrigine (NorthStar Rx LLC) under an ANDA.
-
FDA approval · 2021-11-09FDA Approved: LAMOTRIGINE — Supplemental Application (Torrent Pharmaceuticals Limited)
FDA approved a supplemental application for Lamotrigine from Torrent Pharmaceuticals Limited, authorizing a modification to the approved gen…
-
FDA approval · 2021-11-05FDA Approved: EPRONTIA — Original Application (Azurity Pharmaceuticals, Inc.)
FDA approves EPRONTIA (topiramate) from Azurity Pharmaceuticals, Inc. via an original application for approved indications in epilepsy and m…
-
FDA approval · 2021-10-29FDA Approved: ZARONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Zarontin (ethosuximide) from Parke-Davis Div of Pfizer Inc.
-
FDA approval · 2021-10-29FDA Approved: LAMOTRIGINE — Supplemental Application (Advagen Pharma Limited)
The FDA approved Advagen Pharma Limited's supplemental application for lamotrigine, confirming approval of the requested changes to this gen…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-22FDA Approved: DILANTIN — Supplemental Application (Viatris Specialty LLC)
FDA approved a supplemental application for DILANTIN (extended phenytoin sodium) submitted by Viatris Specialty LLC, introducing the extende…
-
FDA approval · 2021-10-20FDA Approved: CLOBAZAM — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental application for CLOBAZAM (clobazam) from NorthStar RxLLC under ANDA 209796, confirming its status as a gener…
-
FDA approval · 2021-10-15FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin from Quallent Pharmaceuticals Health LLC, resulting in the approval of their generic …
-
FDA approval · 2021-10-14FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) from UCB, Inc., to expand its approved indications for epilepsy.
-
FDA approval · 2021-10-14FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc.
-
FDA approval · 2021-10-07FDA Approved: LEVETIRACETAM — Supplemental Application (Cranbury Pharmaceuticals, LLC)
FDA approved a supplemental application for levetiracetam from Cranbury Pharmaceuticals, LLC under an Abbreviated New Drug Application. The …
-
FDA approval · 2021-10-01FDA Approved: GABAPENTIN — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the original ANDA for gabapentin from XLCare Pharmaceuticals, enabling a generic version of the anticonvulsant.
-
CLINICAL_TRIALS trial_result · 2021-09-29Clinical Trial Update: Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy [Phase 4]
Phase 4 trial evaluating the effects of perampanel on cognition and EEG in patients with epilepsy has completed.
-
FDA label_change · 2021-09-20FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for VIMPAT (lacosamide) filed by UCB, Inc. The approval results in a labeling change to the product …
-
CLINICAL_TRIALS trial_result · 2021-09-16Clinical Trial Update: Correlation of Serum Level of Perampanel (PER) Level to Cerebrospinal Fluid (CSF) Levels of PER [Phase 4]
Phase 4 trial update investigating the correlation between serum perampanel levels and cerebrospinal fluid levels in epilepsy/seizures patie…
-
FDA approval · 2021-09-15FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Vimpat (lacosamide) by UCB, Inc.
-
FDA approval · 2021-09-15FDA Approved: VIMPAT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for VIMPAT (lacosamide) submitted by UCB, Inc. The approval pertains to changes to the drug's la…
-
CLINICAL_TRIALS trial_result · 2021-09-13Clinical Trial Update: Vitamin D Supplementation to Prevent Vitamin D Deficiency for Children With Epilepsy [Phase 3]
Phase 3 trial evaluating vitamin D supplementation to prevent vitamin D deficiency in children with epilepsy has completed.
-
CLINICAL_TRIALS trial_result · 2021-09-05Clinical Trial Update: Buspirone Therapy for Localized Epilepsy [Phase 2]
Phase 2 trial of buspirone for localized epilepsy has been terminated; results posted.
-
FDA approval · 2021-09-02FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for BRIVIACT (brivaracetam) filed by UCB, Inc. The approval confirms modifications to the drug's lab…
-
FDA approval · 2021-09-02FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for Briviact (brivaracetam) filed by UCB, Inc., authorizing changes to its labeling or indication.
-
CLINICAL_TRIALS trial_result · 2021-09-01Clinical Trial Update: A Pilot Study To Evaluate The Effects of Everolimus on Brain mTOR Activity and Cortical Hyperexcitability in TSC and FCD [Phase 2]
Phase 2 pilot study evaluating everolimus on brain mTOR activity and cortical hyperexcitability in epilepsy related to tuberous sclerosis co…
-
FDA approval · 2021-08-27FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
The FDA approved a supplemental application for Briviact (brivaracetam) submitted by UCB, Inc. The approval updates Briviact's labeling and/…
-
FDA approval · 2021-08-27FDA Approved: BRIVIACT — Supplemental Application (UCB, Inc.)
FDA approved a supplemental application for BRIVIACT (brivaracetam) submitted by UCB, Inc., to update its labeling. This approval formalizes…
-
FDA approval · 2021-08-26FDA Approved: TOPIRAMATE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' generic version of topiramate through an original ANDA.